Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

PGEN vs VOR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PGEN Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 7–3 Matrix Metrics)

PGEN Overall Winner 6-Pillar Tally: PGEN 5 – 1 VOR Matrix Metrics: PGEN 7 – 3 VOR

As of Nov 16, 2026, Precigen, Inc. (PGEN) is the stronger overall head-to-head candidate over Vor Biopharma Inc. (VOR) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PGEN carries a Unified Composite Score of 60.2/100 (BUY) at $4.30 (6.9x Forward P/E, 21.4% operating margin), whereas VOR carries 57.8/100 (HOLD) at $18.97 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: PGEN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.6); meanwhile VOR trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PGEN vs VOR
PGEN NASDAQ Head-to-Head Winner
Precigen, Inc. Common Stock
Pharmaceutical Preparations
$4.30
-5.29% 1D
Market Cap $1.6B
TTM Revenue $254M
Forward P/E 6.9x
Beta / 30D Vol 1.74β · 122% Vol
Unified Composite Score
60.2 / 100 BUY
Tech 63.0 Fund 65.0 Flow 67.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.2%), weak momentum, RSI 33
RSI-14: 32.6 · SMA20: $5.48 · SMA50: $6.69
VOR NASDAQ
Vor Biopharma Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$18.97
-2.32% 1D
Market Cap $1.2B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.90β · 61% Vol
Unified Composite Score
57.8 / 100 HOLD
Tech 50.0 Fund 55.0 Flow 66.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.4 · SMA20: $19.48 · SMA50: $19.87

6-Pillar Scorecard Institutional Category Breakdown (PGEN 5 – 1 VOR)

Columns: Metric · PGEN · VOR
1. Valuation Multiples PGEN
Forward P/E 6.9x N/M
Trailing P/E 41.3x 0.1x
PEG Ratio N/M N/M
EV / Revenue 7.0x N/M
2. Growth & Scale PGEN
Revenue Growth (YoY) +2437.6% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $254M N/A
Market Cap $1.6B $1.2B
3. Profitability & Quality PGEN
Gross Margin 74.5% N/A
Operating Margin 21.4% 0.0%
Net Profit Margin 15.6% 0.0%
Return on Equity (ROE) 38.8% -125.4%
4. Balance Sheet & Cash Flow PGEN
Cash Generation (TTM) -$120M -$1.63B
Cash Flow Margin -47.4% N/A
Net Cash / Leverage $135M Net Debt (1.18x D/E) $1.04B Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning VOR
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 95.9% (13th %ile) 120.2% (6th %ile)
Put/Call OI Skew 0.06x (Call-Skewed) 2.03x (Put-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat PGEN
OpEx & R&D Intensity 53.1% of Rev ($135M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PGEN (7) vs VOR (3)
Institutional Metric PGEN VOR Criterion Row Edge
Market Capitalization
Scale
$1.6B $1.2B Larger Scale PGEN
Trailing P/E Ratio
Valuation
41.3x 0.1x Lower Multiple VOR
Forward P/E Ratio
Valuation
6.9x N/M Lower Multiple PGEN
Revenue Growth (YoY)
Growth
+2437.6% +0.0% Higher Growth PGEN
Operating Margin (TTM)
Profitability
21.4% 0.0% Higher Margin PGEN
Net Profit Margin
Profitability
15.6% 0.0% Higher Margin PGEN
Return on Equity (ROE)
Capital Efficiency
38.8% -125.4% Higher ROE PGEN
52-Week Range Position
Momentum
21% ($3–$9) 64% ($6–$26) Stronger Trend VOR
Beta / 30D Volatility
Risk Regime
1.74β · 122% Vol 1.90β · 61% Vol Lower Realized Risk VOR
Unified Institutional Score
Composite Signal
60.2 / 100 (BUY) 57.8 / 100 (HOLD) Higher Composite PGEN
Trailing 12M Revenue (USD)
Operating Scale
$254M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
74.5% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 7.0x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$120M ($135M Net Debt (1.18x D/E)) -$1.63B ($1.04B Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VOR +37.86 pp
PGEN: -32.65% · VOR: +5.21%
3M Horizon VOR +17.79 pp
PGEN: -36.3% · VOR: -18.51%
6M Horizon VOR +28.6 pp
PGEN: +5.65% · VOR: +34.25%
1Y Horizon VOR +83.16 pp
PGEN: +11.4% · VOR: +94.56%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PGEN vs VOR. Trailing 12-month operating profitability (PGEN 21.4% vs VOR 0.0%) and valuation multiples (PGEN 6.9x vs VOR N/M Forward P/E) are benchmarked directly in Pillar 4 below.

PGEN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$254M
Gross Margin74.5%
Op. Margin21.4%
ROE / Fwd P/E38.8% · 6.9x
VOR ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-125.4% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PGEN BREAKDOWN
61d in phase · OBV DISTRIBUTION
Current IV 95.9%
IV Percentile 13th %ile
Put/Call OI Skew 0.06x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact PGEN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VOR CONSOLIDATION
52d in phase · OBV NEUTRAL
Current IV 120.2%
IV Percentile 6th %ile
Put/Call OI Skew 2.03x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact VOR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PGEN Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $1.6B market capitalization and 21.4% operating margin.
OpEx & R&D Reinvestment 53.1% of Rev ($135M)
90D Engineering Disclosures 0 Published
VOR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.2B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PGEN vs VOR Key Questions & Quantitative Answers

As of Nov 16, 2026, Precigen, Inc. (PGEN) is the stronger overall head-to-head candidate over Vor Biopharma Inc. (VOR) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PGEN carries a Unified Composite Score of 60.2/100 (BUY) at $4.30 (6.9x Forward P/E, 21.4% operating margin), whereas VOR carries 57.8/100 (HOLD) at $18.97 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: PGEN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.6); meanwhile VOR trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PGEN leads the Growth & Scale pillar: PGEN posts +2437.6% YoY revenue growth and +0.0% YoY earnings growth on $254M TTM revenue (74.5% gross margin, 21.4% operating margin), compared with VOR at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, PGEN generates $254M in USD-normalized revenue versus N/A for VOR. In operating R&D and SG&A reinvestment, PGEN deploys 53.1% of Rev ($135M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VOR.

PGEN screens cheaper on headline valuation multiples. PGEN trades at 6.9x Forward P/E, 41.3x Trailing P/E, N/M PEG, and 7.0x EV/Revenue (-47.4% FCF margin), whereas VOR trades at N/M Forward P/E, 0.1x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PGEN (38.8% ROE) versus VOR (-125.4% ROE) capital efficiency.

In options market volatility and institutional positioning, PGEN carries 95.9% implied volatility (13th %ile, Compressed (<25th %ile)), a 0.06x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.74β · 122% Vol realized risk). By comparison, VOR carries 120.2% implied volatility (6th %ile, Compressed (<25th %ile)), a 2.03x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.90β · 61% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.